NCT01974687View on ClinicalTrials.gov

Single and Multiple Dose Study of Uprifosbuvir (MK-3682/IDX21437) in Healthy and Hepatitis C Virus (HCV)-Infected Participants (MK-3682-001)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

178

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

September 2, 2015

Study Completion Date

September 11, 2015

Conditions
Chronic Hepatitis C
Interventions
DRUG

Uprifosbuvir

Uprifosbuvir 5 mg, 25 mg, or 50 mg capsule, or 150 mg tablet, administered by mouth.

DRUG

Placebo

Matching placebo to uprifosbuvir capsule administered by mouth.

DRUG

Itraconazole

Itraconazole is supplied as 10 mg/mL oral solution or 100 mg capsules administered by mouth.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01974687 - Single and Multiple Dose Study of Uprifosbuvir (MK-3682/IDX21437) in Healthy and Hepatitis C Virus (HCV)-Infected Participants (MK-3682-001) | Biotech Hunter | Biotech Hunter